Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
复制标题
DOI：
10.1371/journal.pone.0117125
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Amogne W
中科院分区：
文献类型：
--
作者：
Gleason RL Jr;Caulk AW;Seifu D;Parker I;Vidakovic B;Getenet H;Assefa G;Amogne W
接受抗逆转录病毒治疗的HIV患者显示血脂异常、脂肪代谢障碍和心血管疾病（CVD）的发病率升高。然而，大多数研究都集中在发达国家的队列中，埃塞俄比亚和撒哈拉以南非洲的这些合并症的数据较少。成人HIV阴性（n = 36）、初治（n = 51）、依法韦仑（EFV）治疗（n = 91）、奈韦拉平（NVP）治疗（n = 95）或利托那韦加强洛匹那韦（LPV/r）治疗（n=44）受试者从埃塞俄比亚阿迪斯的黑狮医院招募。通过压平张力计测量主动脉压、增强压和脉搏波速度（PWV），通过无创超声测量颈动脉内膜中层厚度（cIMT）和颈动脉僵硬度以及肱动脉血流介导的扩张（FMD）。体重指数，腰臀比（WHR），皮褶厚度和自我报告的脂肪再分布被用来量化脂肪代谢障碍。检测CD 4+细胞计数、血浆HIV RNA水平、空腹血糖、总胆固醇、HDL胆固醇和LDL胆固醇、甘油三酯、hsCRP、sVCAM-1、sICAM-1、瘦素和全血细胞计数。与NVP治疗受试者相比，EFV和LPV/r治疗受试者的PWV和标准化cIMT升高，FMD受损;与初治受试者相比，EFV和LPV/r治疗受试者的标准化cIMT也升高，FMD受损。各组之间的cIMT无统计学差异。接受治疗的受试者表现出血脂异常、炎症和脂肪代谢障碍的标志物升高。PWV与年龄、目前使用的EFV和LPV/r、心率、血压、甘油三酯、LDL和hsCRP相关，FMD与年龄、HIV持续时间、WHR和血糖相关，cIMT与年龄、目前使用的EFV、皮褶厚度和血压相关。目前的EFV或LPV/r治疗，而不是NVP治疗，与动脉粥样硬化标志物升高相关，这可能涉及与传统危险因素不同的机制。
HIV patients on antiretroviral therapy have shown elevated incidence of dyslipidemia, lipodystrophy, and cardiovascular disease (CVD). Most studies, however, focus on cohorts from developed countries, with less data available for these co-morbidities in Ethiopia and sub-Saharan Africa. Adult HIV-negative (n = 36), treatment naïve (n = 51), efavirenz (EFV)-treated (n = 91), nevirapine (NVP)-treated (n = 95), or ritonavir-boosted lopinavir (LPV/r)-treated (n=44) subjects were recruited from Black Lion Hospital in Addis Ababa, Ethiopia. Aortic pressure, augmentation pressure, and pulse wave velocity (PWV) were measured via applanation tonometry and carotid intima-media thickness (cIMT) and carotid arterial stiffness, and brachial artery flow-mediated dilation (FMD) were measured via non-invasive ultrasound. Body mass index, waist-to-hip circumference ratio (WHR), skinfold thickness, and self-reported fat redistribution were used to quantify lipodystrophy. CD4+ cell count, plasma HIV RNA levels, fasting glucose, total-, HDL-, and LDL-cholesterol, triglycerides, hsCRP, sVCAM-1, sICAM-1, leptin and complete blood count were measured. PWV and normalized cIMT were elevate and FMD impaired in EFV- and LPV/r-treated subjects compared to NVP-treated subjects; normalized cIMT was also elevated and FMD impaired in the EFV- and LPV/r-treated subjects compared to treatment-naïve subjects. cIMT was not statistically different across groups. Treated subjects exhibited elevated markers of dyslipidemia, inflammation, and lipodystrophy. PWV was associated with age, current EFV and LPV/r used, heart rate, blood pressure, triglycerides, LDL, and hsCRP, FMD with age, HIV duration, WHR, and glucose, and cIMT with age, current EFV use, skinfold thickness, and blood pressure. Current EFV- or LPV/r-treatment, but not NVP-treatment, correlated with elevated markers of atherosclerosis, which may involve mechanisms distinct from traditional risk factors.
登录
查看更多内容
影响因子：
2.4
作者：
Hansen, Laura;Parker, Ivana;Gleason, Rudolph L., Jr.
通讯作者：
Gleason, Rudolph L., Jr.
影响因子：
6.4
作者：
Grubb, JR;Dejam, A;Gladwin, MT
通讯作者：
Gladwin, MT
影响因子：
1.2
作者：
Falcone, E. Liana;Mangili, Alexandra;Wanke, Christine A.
通讯作者：
Wanke, Christine A.
DOI：
10.1097/qai.0b013e31815e7453
发表时间：
2008-03-01
影响因子：
3.6
作者：
Buchacz, Kate;Weidle, Paul J.;Brooks, John T.
通讯作者：
Brooks, John T.
DOI：
10.3109/15419069509081285
发表时间：
1995-01-01
期刊：
CELL ADHESION AND COMMUNICATION
影响因子：
--
作者：
GATTEGNO, L;BENTATAPEYSSARE, M;FERRIERE, F
通讯作者：
FERRIERE, F